ACHE and myasthenia gravis: Within our cohort, 13 (7 mild, 2 moderate and 4 severe) out of 20 individuals from our CMS cohort are receiving a pharmacological treatment consisting of pyridostigmine, an acetylcholinesterase inhibitor used to treat muscle weakness in myasthenia gravis and CMS96.